Aptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Aptose Biosciences (TSX: APS), a clinical-stage precision oncology company, has announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto, scheduled for May 5-6, 2025. The company, which is developing a tuspetinib (TUS) based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML) patients, will be represented by Dr. William G. Rice, Chairman, President and CEO.
Dr. Rice will deliver a corporate presentation on May 5, 2025, at 3:00 p.m. EDT. The presentation will be available via webcast and will also be accessible on the Aptose website. Additionally, the management team will be conducting one-on-one meetings during the conference, which interested parties can schedule through their conference representatives.
Aptose Biosciences (TSX: APS), un'azienda di oncologia di precisione in fase clinica, ha annunciato la sua partecipazione alla 2025 Bloom Burton & Co. Healthcare Investor Conference a Toronto, prevista per il 5 e 6 maggio 2025. L'azienda, che sta sviluppando una terapia tripla di prima linea a base di tuspetinib (TUS) per pazienti con leucemia mieloide acuta (LMA) di nuova diagnosi, sarà rappresentata dal Dott. William G. Rice, Presidente, CEO e Chairman.
Il Dott. Rice terrà una presentazione aziendale il 5 maggio 2025 alle 15:00 EDT. La presentazione sarà disponibile in webcast e accessibile anche sul sito web di Aptose. Inoltre, il team di gestione terrà incontri individuali durante la conferenza, che potranno essere programmati dagli interessati tramite i loro rappresentanti della conferenza.
Aptose Biosciences (TSX: APS), una empresa de oncología de precisión en fase clínica, ha anunciado su participación en la Conferencia de Inversores en Salud 2025 de Bloom Burton & Co. en Toronto, programada para el 5 y 6 de mayo de 2025. La compañía, que desarrolla una terapia triple de primera línea basada en tuspetinib (TUS) para pacientes recién diagnosticados con leucemia mieloide aguda (LMA), estará representada por el Dr. William G. Rice, presidente, director ejecutivo y chairman.
El Dr. Rice ofrecerá una presentación corporativa el 5 de mayo de 2025 a las 3:00 p.m. EDT. La presentación estará disponible vía webcast y también se podrá acceder a ella en el sitio web de Aptose. Además, el equipo directivo realizará reuniones individuales durante la conferencia, las cuales los interesados podrán agendar a través de sus representantes en el evento.
Aptose Biosciences (TSX: APS)는 임상 단계의 정밀 종양학 회사로, 2025년 5월 5일부터 6일까지 토론토에서 열리는 2025 Bloom Burton & Co. 헬스케어 투자자 컨퍼런스에 참여한다고 발표했습니다. 이 회사는 새로 진단된 급성 골수성 백혈병(AML) 환자를 위한 tuspetinib(TUS) 기반 3중 약물 1차 치료법을 개발 중이며, 윌리엄 G. 라이스 박사가 회장 겸 사장, CEO로서 회사를 대표할 예정입니다.
라이스 박사는 2025년 5월 5일 오후 3시(동부 표준시)에 기업 발표를 진행합니다. 발표는 웹캐스트로 제공되며 Aptose 웹사이트에서도 시청할 수 있습니다. 또한 경영진은 컨퍼런스 기간 동안 1:1 미팅을 진행하며, 관심 있는 분들은 컨퍼런스 담당자를 통해 일정을 예약할 수 있습니다.
Aptose Biosciences (TSX : APS), une société d'oncologie de précision en phase clinique, a annoncé sa participation à la conférence des investisseurs en santé Bloom Burton & Co. 2025 à Toronto, prévue les 5 et 6 mai 2025. L'entreprise, qui développe une thérapie de première ligne triple à base de tuspetinib (TUS) pour les patients nouvellement diagnostiqués avec une leucémie myéloïde aiguë (LMA), sera représentée par Dr William G. Rice, président, directeur général et président du conseil d'administration.
Le Dr Rice présentera une conférence d'entreprise le 5 mai 2025 à 15h00 EDT. La présentation sera disponible en webcast et accessible sur le site web d’Aptose. De plus, l’équipe de direction tiendra des réunions individuelles lors de la conférence, que les personnes intéressées pourront organiser via leurs représentants de la conférence.
Aptose Biosciences (TSX: APS), ein klinisch fortgeschrittenes Präzisions-Onkologie-Unternehmen, hat seine Teilnahme an der 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto angekündigt, die für den 5. bis 6. Mai 2025 geplant ist. Das Unternehmen, das eine dreifache Erstlinientherapie auf Basis von Tuspetinib (TUS) für neu diagnostizierte Patienten mit akuter myeloischer Leukämie (AML) entwickelt, wird durch Dr. William G. Rice, Vorsitzender, Präsident und CEO, vertreten.
Dr. Rice wird am 5. Mai 2025 um 15:00 Uhr EDT eine Unternehmenspräsentation halten. Die Präsentation wird per Webcast verfügbar sein und auch auf der Aptose-Website abrufbar sein. Darüber hinaus wird das Management-Team während der Konferenz Einzelgespräche führen, die von Interessenten über ihre Konferenzvertreter vereinbart werden können.
- None.
- None.
SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced that the Aptose management team will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference being held in Toronto, May 5-6, 2025.
Dr. William G. Rice, Chairman, President and CEO of Aptose, will present on May 5, 2025 and will be hosting one-on-one meetings during the conference. To schedule a one-on-one meeting with Aptose please contact your conference representative.
| 2025 Bloom Burton & Co. Healthcare Investor Conference | |
| Date: | Monday, May 5, 2025 |
| Presentation Time: | 3:00 p.m. EDT |
| Format: | Corporate Presentation and Webcast |
| Speaker: | William G. Rice, PhD, Chairman, President and Chief Executive Officer |
| Webcast: | Link |
| (https://event.summitcast.com/view/hG2KhRan38C8o5wZiWyxNK/gmdcbaMxMaML5y8VPDckgT) | |
The corporate presentation will be available on the Aptose website here.
About the Conference
The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from premier Canadian publicly traded and private companies through presentations and private meetings. For more information, please visit: bloomburton.com/conference.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements relating to the Company’s growth, plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “hope” “should”, “would”, “may”, “potential” and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release.
Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.
For further information, please contact:
Aptose Biosciences Inc.
Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com
FAQ
When and where is Aptose (APTO) presenting at the 2025 Bloom Burton Healthcare Conference?
What is the main drug therapy Aptose (APTO) is developing in 2025?
How can investors attend Aptose's (APTO) one-on-one meetings at the 2025 Bloom Burton Conference?
Where can investors access Aptose's (APTO) 2025 Bloom Burton Conference presentation?
